PowderJect Pharmaceuticals PLC has announced that following authorization by its shareholders at the company’s Extraordinary General Meeting on Friday September 29, it has completed its acquisition of Medeva’s vaccines business from Celltech Group Plc. The acquisition includes a range of marketed vaccines, which will be sold under the established Evans Vaccines brand, and one of Europe’s leading biological production facilities located at Speke in the UK. The business will be merged with PowderJect’s wholly-owned subsidiary PowderJect Vaccines, to create a fully integrated vaccine business as a division of PowderJect Pharmaceuticals plc.
Commenting on today’s announcement, Dr Paul R. Drayson, Chairman and CEO of PowderJect said, “I am extremely pleased that we have completed the acquisition of Medeva Vaccines, creating a truly world- class vaccine business. By combining existing marketed products with PowderJect’s pipeline of conventional vaccines and our global leadership in the field of DNA vaccines, we are well positioned to capture a significant share of the rapidly growing $6.5 billion vaccines market.”
PowderJect‘s technology focus is on the powder injection of medicines, a field in which it leads the world.
The company was established in 1993 to exploit research at Oxford University into vaccine, drug and diagnostics delivery, and is developing a broad range of novel products in-house and for leading pharmaceutical companies based upon the use of its proprietary powder injection systems.
With a range of products sold under its Evans Vaccines brand, PowderJect is the world’s 6th largest vaccines company.